查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1922939

可溶解微针贴片市场：依聚合物类型、应用、最终用户和通路划分－2026-2032年全球预测

Dissolvable Microneedle Patches Market by Polymer Type, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，可溶解微针贴片市场价值将达到 5.3456 亿美元，到 2026 年将成长至 6.2979 亿美元，到 2032 年将达到 17.8913 亿美元，复合年增长率为 18.83%。

关键市场统计数据
基准年 2025 5.3456亿美元
预计年份：2026年 6.2979亿美元
预测年份 2032 17.8913亿美元
复合年增长率 (%) 18.83%

对可溶解微针贴片的科学进步和医疗保健需求进行了简洁的策略概述，推动了其在临床和消费市场的应用。

可溶解微针贴片融合了材料科学、药物递送创新和以患者为中心的医疗保健设计，有望重新定义经皮给药方式。这些装置可在表皮内溶解，递送活性成分，且不会产生锐器废弃物，并可实现无痛、微创给药，符合现代医疗对安全性、依从性和便捷性的追求。聚合物化学、精密微加工和无菌生产技术的进步正在融合，以降低技术壁垒，并将临床应用从治疗领域扩展到美容领域。

材料创新、监管政策的明确性以及以患者为中心的给药模式如何改变可溶解微针贴片的研发路径和商业性机会？

随着技术的成熟、监管政策的明朗化以及新兴应用案例的涌现，可溶解微针贴片的市场格局正在迅速变化，商业化路径也随之重塑。材料创新使得产品从一次性试点原型过渡到适用于严格无菌生产的可重复配方。与科技进步同步，医疗服务模式也正在改变。便利的施用器和清晰的说明书让非专业使用者也能轻鬆上手，居家给药和诊所内自我护理正变得越来越可行。这些趋势正在减少传统肠外给药疗法带来的阻力，为过去因害怕针头和就医障碍而受困的患者群体开闢新的途径。

美国不断变化的关税政策对製造商的营运和策略影响迫使他们重新思考微针产品的采购、在地化和供应链韧性。

目前及预期中的关税政策对从事可溶解微针贴片生产和分销的企业具有独特的营运和策略影响。聚合物、精密模具和成品贴片的进口关税提高，增加了依赖全球供应链的製造商的到岸成本，促使采购部门重新评估供应商合约和库存策略。为此，一些製造商正在加快关键原材料的在地采购，实现供应商多元化，并将关税风险纳入总成本模型，以维持利润率和专案进度。

细分市场分析揭示了应用、聚合物选择、终端用户需求和通路如何共同影响产品设计、监管要求和商业化路径。

可溶解微针贴片的細項分析突显了不同应用、聚合物选择、终端用户和分销管道所带来的不同应用路径和技术优先顺序。依应用划分，市场可分为化妆品及药品两大应用领域，而药品开发可进一步细分为止痛药製剂、胰岛素输送系统及候选疫苗。每个治疗领域都提出了独特的性能、稳定性和监管要求，这些要求会影响製剂策略和临床试验设计。

美洲、欧洲、中东和非洲以及亚太地区的区域法规结构、製造业生态系统和商业性动态将如何以独特的方式影响技术采纳路径和供应策略

区域趋势将对可溶解微针贴片的推广应用时间表、监管要求和製造地产生显着影响。在美洲，监管机构和医疗支付方对能够提高患者依从性并减轻临床负担的技术的接受度不断提高，为门诊和居家医疗的试验计画创造了有利环境。尤其是在美国，政府正加大对国内生产能力的投资，并积极进行公私合营倡议，以支持疫苗和生物製药递送技术的创新。

提供竞争洞察，将製药赞助商、医疗设备专家、材料技术创新者和契约製造製造商联繫起来，以加速商业化和规模化生产。

溶解性微针贴片领域的竞争动态由成熟的製药公司、专业的器材开发商、材料供应商以及专注于平台技术的敏捷型新创公司共同塑造。领先的製药公司利用其监管经验和临床Start-Ups基础设施来推进候选疗法的研发，而器械专家则提供微加工技术和组装规模化生产能力。材料公司和聚合物创新者在上游工程，他们提供针对溶解速率、机械强度和生物相容性优化的材料等级和配方。

明确且优先的行动方案，协调经营团队在配方设计、监管规划、供应链韧性、临床证据、伙伴关係和永续性的工作，以加速产品推广和规模化应用。

行业领导者应优先考虑技术选择、监管策略和商业性执行的整合方法，以抓住短期机会并建立长期韧性。首先，应投资于聚合物选择和配方开发，以平衡机械性能、生物相容性和可扩展的生产工艺，从而减少下游技术转移的阻力。其次，应儘早制定监管蓝图，以解决组合产品分类、无菌检验和人体工学测试等问题，从而与监管机构和支付方进行高效沟通。

一种透明且可重复的调查方法，结合了相关人员访谈、技术文献、监管分析、专利研究和供应链检验，以支援策略决策。

本研究整合了一手和二手资料，得出严谨且可用于决策的分析结果。一手资料包括对药物研发、医疗设备设计、材料供应、临床实践和契约製造等领域的相关人员进行结构化访谈，以及与监管事务专家和采购主管进行讨论，以获得关于生产限制、监管预期、临床终点和商业化准备情况的第一手资讯。

简明扼要的结论整合了技术可行性、监管要求和策略重点，有助于指导相关人员实现永续的采用和商业化。

溶解性微针贴片正处于一个策略转折点，科学进步、监管力度和不断变化的护理模式在此交汇，为治疗和美容应用开闢了一条商业性化的道路。该技术的优势——减轻手术疼痛、消除锐器废弃物以及可自行使用——满足了特定的临床和消费者需求，而聚合物科学和製造技术的进步正在降低可靠的大规模生产的门槛。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依聚合物类型分類的可溶解微针贴片市场

  • 几丁聚醣
  • 玻尿酸
  • 聚乳酸
  • 聚乙烯吡咯烷酮

9. 按应用分類的可溶解微针贴片市场

  • 化妆品
  • 製药
    • 止痛药
    • 胰岛素
    • 疫苗

第十章 依终端用户分類的可溶解微针贴片市场

  • 诊所
  • 家庭医疗保健
  • 医院
  • 研究所

第十一章 依通路分類的可溶解微针贴片市场

  • 医院药房
  • 网路药房
  • 零售药房

第十二章 各地区可溶解微针贴片市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 按组别分類的可溶解微针贴片市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国可溶解微针贴片市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

15. 美国可溶解微针贴片市场

第十六章 中国可溶微针贴片市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • 111Skin
  • 3M Company
  • AdminMed, Inc.
  • AND SHINE
  • Beijing CAS Microneedle Technology
  • Corium, Inc.
  • CosMED Pharmaceutical Co., Ltd.
  • ESK GmbH
  • Hero Cosmetics
  • Kindeva Drug Delivery
  • LTS Lohmann Therapie-Systeme AG
  • Micron Biomedical Inc.
  • Microneedle Biosystems NV
  • Micropoint Technologies
  • NanoPass Technology Ltd.
  • Nissha Co., Ltd.
  • Rani Therapeutics LLC
  • Raphas Co., Ltd.
  • Shiseido Company, Limited
  • Skyn Iceland
  • Vaxess Technologies, Inc.
  • Zhuhai Youwe Biotechnology
  • Zosano Pharma Corp.
Product Code: MRR-867BED9A9E6D

The Dissolvable Microneedle Patches Market was valued at USD 534.56 million in 2025 and is projected to grow to USD 629.79 million in 2026, with a CAGR of 18.83%, reaching USD 1,789.13 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 534.56 million
Estimated Year [2026] USD 629.79 million
Forecast Year [2032] USD 1,789.13 million
CAGR (%) 18.83%

A succinct strategic introduction summarizing the scientific advances and healthcare imperatives driving dissolvable microneedle patches toward broader clinical and consumer adoption

Dissolvable microneedle patches represent a convergence of materials science, drug delivery innovation, and patient-centric healthcare design, poised to redefine transdermal administration. These devices dissolve in the epidermis to deliver active compounds without generating sharps waste, enabling painless, minimally invasive dosing that aligns with modern priorities for safety, adherence, and convenience. Advances in polymer chemistry, precision microfabrication, and sterile manufacturing have collectively reduced technical barriers, while increasing clinical exploration across therapeutic and cosmetic domains.

As interest grows from pharmaceutical developers, cosmetic formulators, and contract manufacturers, the ecosystem has shifted from proof-of-concept research toward scalable production and regulatory engagement. Clinical programs have expanded beyond topical analgesia to include systemic biologics such as insulin and vaccine candidates, reflecting the technology's versatility. Concurrently, regulatory bodies have issued guidance and established frameworks that emphasize quality-by-design, biocompatibility testing, and robust sterility assurance. Taken together, these dynamics create a near-term imperative for leaders to align R&D pipelines, supply chain strategies, and health-economic narratives to capture uptake as adoption moves from niche trials to routine clinical and consumer use.

How materials breakthroughs, regulatory clarity, and patient-centric delivery models are transforming development pathways and commercial opportunities for dissolvable microneedle patches

The landscape for dissolvable microneedle patches is changing rapidly as technology maturation, regulatory clarity, and new use cases converge to reshape commercialization pathways. Materials innovation has enabled a shift from single-use exploratory prototypes to reproducible formulations suitable for stringent sterile production. This technical progression is matched by a shift in care delivery models: home administration and clinic-based self-care are increasingly viable, supported by user-friendly applicators and clear instructions for non-specialist users. These trends reduce the friction traditionally associated with parenteral therapies and open channels to patient populations that previously struggled with needle aversion or access barriers.

Parallel to technical and delivery changes, the regulatory environment is responding with clearer expectations for device-drug combinations, sterility controls, and biocompatibility. Payors and procurement bodies are beginning to evaluate value propositions that emphasize adherence, reduced clinic visits, and lower sharps waste disposal costs. Strategic partnerships between pharmaceutical sponsors, device specialists, and contract manufacturers are accelerating, enabling scale-up and multi-site distribution. As a result, incumbent assumptions about formulation limits and clinical applicability are being overturned, creating a landscape in which novel therapeutic and preventive applications can be commercialized more rapidly than a few years ago.

Operational and strategic consequences of evolving United States tariff policy that compel manufacturers to rethink sourcing, localization, and supply chain resilience for microneedle products

Current and prospective tariff policies introduce a distinct set of operational and strategic effects for organizations involved in the production and distribution of dissolvable microneedle patches. Increased import duties on polymers, precision tooling, and finished patches can raise landed costs for manufacturers that rely on global supply chains, prompting procurement teams to reevaluate supplier contracts and inventory strategies. In response, some manufacturers are accelerating localization of critical inputs, diversifying supplier bases, and incorporating tariff risk into total cost models to preserve margin and program timelines.

Beyond direct cost implications, tariff regimes influence sourcing decisions for specialized polymers and device components, shifting investment toward vertically integrated production or near-shore partnerships that reduce exposure to cross-border duties. Regulatory compliance and customs classification become operational priorities, as misclassification can trigger retroactive liabilities. To mitigate disruption, firms are investing in scenario planning, tariff engineering exercises, and collaborative engagements with trade consultants. These adaptive measures are altering capital allocation and go-to-market sequencing, encouraging a careful balance between cost optimization and maintaining the agility needed for clinical supply and commercial launches.

Segment-driven insights revealing how applications, polymer choices, end-user requirements, and distribution channels collectively shape product design, regulatory needs, and commercialization pathways

Segmentation insights for dissolvable microneedle patches highlight differentiated adoption paths and technical priorities across application, polymer selection, end user, and distribution channel. When viewed by application, the market is divided between cosmetic use cases and pharmaceutical indications, with pharmaceutical development further segmented into analgesic formulations, insulin delivery systems, and vaccine candidates; each therapeutic area imposes distinct performance, stability, and regulatory requirements that influence formulation strategies and clinical trial design.

Polymer choice is a core technical determinant, with chitosan offering biodegradability and mucoadhesive properties, hyaluronic acid providing hydrating and dermal compatibility advantages, polylactic acid contributing mechanical strength and controlled dissolution characteristics, and polyvinylpyrrolidone supplying solubility and ease of processing. End-user contexts shape usability and packaging requirements: clinics and hospitals demand batch traceability and compatibility with sterile workflows, home healthcare environments prioritize ease of self-administration and patient instructions, and research laboratories focus on formulation flexibility and rapid iteration. Distribution pathways create additional constraints and opportunities, where hospital pharmacies require predictable cold chain or controlled storage practices, online pharmacies emphasize clear labeling and logistics for direct-to-consumer delivery, and retail pharmacies must accommodate point-of-sale counseling and in-store inventory management. Collectively, these segments inform product design, regulatory strategy, and commercial prioritization, guiding where clinical evidence and supply investments will most rapidly translate into adoption.

How regional regulatory frameworks, manufacturing ecosystems, and commercial dynamics in the Americas, Europe Middle East & Africa, and Asia-Pacific uniquely influence adoption pathways and supply strategies

Regional dynamics exert a pronounced influence on adoption timelines, regulatory requirements, and manufacturing footprints for dissolvable microneedle patches. In the Americas, regulatory agencies and healthcare payors are increasingly receptive to technologies that improve adherence and reduce clinical burden, producing an environment favorable to pilot programs in outpatient clinics and home healthcare. The United States in particular shows growing investment in domestic manufacturing capacity and public-private initiatives that support vaccine and biologic delivery innovations.

In Europe, Middle East & Africa, fragmented regulatory pathways and diverse reimbursement environments create both challenges and localized opportunities, as national health systems prioritize cost-effective interventions and sustainability. Regulatory harmonization efforts and multi-country clinical programs can accelerate broader uptake, but companies must tailor dossiers and distribution strategies to country-specific requirements. In the Asia-Pacific region, a combination of large patient populations, strong contract manufacturing ecosystems, and proactive regulatory authorities has led to rapid scaling of clinical research and manufacturing partnerships. Regional supply chain strategies increasingly favor geographically distributed production to reduce lead times and respond to local demand fluctuations, while commercial approaches emphasize partnerships with local distributors, pharmacy chains, and digital health platforms to reach diverse end users.

Insight into the competitive ecosystem where pharmaceutical sponsors, device specialists, materials innovators, and contract manufacturers converge to accelerate commercialization and scale

Competitive dynamics in the dissolvable microneedle patch space are shaped by a blend of established pharmaceutical manufacturers, specialized device developers, materials suppliers, and nimble startups focusing on platform technologies. Leading pharmaceutical firms are leveraging regulatory experience and clinical trial infrastructure to advance therapeutic candidates, while device specialists contribute microfabrication expertise and assembly scale-up capabilities. Materials companies and polymer innovators play a critical upstream role by delivering grades and formulations optimized for dissolution kinetics, mechanical strength, and biocompatibility.

Startups and academic spinouts often lead on early-stage clinical proof-of-concept and novel applicator designs, creating attractive licensing or partnership opportunities for larger organizations seeking accelerated entry. Contract development and manufacturing organizations are emerging as pivotal partners for scale-up, offering sterile fill-finish, precision micromolding, and quality management systems that meet combination product expectations. Intellectual property, regulatory filings, and a growing base of clinical evidence are increasingly the differentiators that determine which firms move from pilot programs to commercial launches. Strategic alliances, co-development agreements, and selective M&A activity are expected to continue as companies align complementary capabilities across materials, device engineering, and clinical access.

Clear, prioritized actions for executives to align formulation, regulatory planning, supply resilience, clinical evidence, partnerships, and sustainability to accelerate adoption and scale

Industry leaders should prioritize an integrated approach that aligns technology choices, regulatory strategy, and commercial execution to capture near-term opportunities while building long-term resilience. First, invest in polymer selection and formulation development that balance mechanical performance with biocompatibility and scalable manufacturing processes to reduce downstream tech transfer friction. Second, develop a regulatory roadmap early that addresses combination product classification, sterility validations, and human factors testing, enabling more efficient interactions with regulators and payors.

Third, build supply chain redundancy through qualified alternate suppliers and regional manufacturing partnerships to mitigate tariff exposure and logistical disruption. Fourth, create clinical development programs that generate compelling evidence for adherence, safety, and comparative effectiveness in target end-user settings such as clinics, hospitals, and home healthcare environments. Fifth, pursue strategic collaborations with contract manufacturers to accelerate sterile scale-up and with digital health providers to support patient education and adherence monitoring. Finally, embed sustainability and waste-reduction narratives into product positioning to resonate with procurement and health-system stakeholders, while ensuring commercial materials and packaging meet retail and online distribution requirements.

A transparent and reproducible research methodology combining stakeholder interviews, technical literature, regulatory analysis, patent review, and supply chain validation to support strategic decisions

This research synthesizes primary and secondary evidence to produce a rigorous, decision-ready analysis. Primary research included structured interviews with stakeholders across pharmaceutical development, device engineering, materials supply, clinical practice, and contract manufacturing, along with consultations with regulatory affairs specialists and procurement leaders. These engagements provided firsthand perspectives on manufacturing constraints, regulatory expectations, clinical endpoints of interest, and commercial readiness.

Secondary research leveraged peer-reviewed literature, patent filings, clinical trial registries, and public regulatory guidance to map technological capabilities, intellectual property trends, and the evolving evidence base. Technical validation included cross-referencing polymer performance data with materials characterization reports and reviewing sterility and stability protocols used in combination product submissions. Supply chain mapping and tariff impact analysis were informed by trade data, customs classifications, and input from logistics experts. Findings were triangulated across sources and reviewed by subject matter experts to ensure coherence, robustness, and practical relevance to product development and commercialization decisions.

A concise conclusion that synthesizes technological promise, regulatory imperatives, and strategic priorities to guide stakeholders toward sustainable adoption and commercialization

Dissolvable microneedle patches occupy a strategic inflection point where scientific progress, regulatory momentum, and shifting care models converge to create commercially viable pathways for both therapeutic and cosmetic applications. The technology's strengths-including reduced procedural pain, elimination of sharps waste, and potential for self-administration-address concrete clinical and consumer needs, while polymer science and manufacturing improvements are lowering the barriers to reliable production at scale.

Realizing the potential of these platforms requires coordinated attention to formulation optimization, regulatory engagement, robust clinical evidence generation, and resilient supply chains that account for trade policy dynamics. Firms that integrate these elements with targeted commercial strategies-tailored by application, polymer choice, end-user setting, and distribution channel-will be best positioned to convert scientific promise into sustained adoption. Strategic partnerships, careful IP management, and proactive tariff and logistics planning will further distinguish leaders as the technology moves beyond early trials into broader clinical and consumer use.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Dissolvable Microneedle Patches Market, by Polymer Type

  • 8.1. Chitosan
  • 8.2. Hyaluronic Acid
  • 8.3. Polylactic Acid
  • 8.4. Polyvinylpyrrolidone

9. Dissolvable Microneedle Patches Market, by Application

  • 9.1. Cosmetic
  • 9.2. Pharmaceutical
    • 9.2.1. Analgesic
    • 9.2.2. Insulin
    • 9.2.3. Vaccine

10. Dissolvable Microneedle Patches Market, by End User

  • 10.1. Clinics
  • 10.2. Home Healthcare
  • 10.3. Hospitals
  • 10.4. Research Laboratories

11. Dissolvable Microneedle Patches Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Dissolvable Microneedle Patches Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Dissolvable Microneedle Patches Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Dissolvable Microneedle Patches Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Dissolvable Microneedle Patches Market

16. China Dissolvable Microneedle Patches Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. 111Skin
  • 17.6. 3M Company
  • 17.7. AdminMed, Inc.
  • 17.8. AND SHINE
  • 17.9. Beijing CAS Microneedle Technology
  • 17.10. Corium, Inc.
  • 17.11. CosMED Pharmaceutical Co., Ltd.
  • 17.12. ESK GmbH
  • 17.13. Hero Cosmetics
  • 17.14. Kindeva Drug Delivery
  • 17.15. LTS Lohmann Therapie-Systeme AG
  • 17.16. Micron Biomedical Inc.
  • 17.17. Microneedle Biosystems NV
  • 17.18. Micropoint Technologies
  • 17.19. NanoPass Technology Ltd.
  • 17.20. Nissha Co., Ltd.
  • 17.21. Rani Therapeutics LLC
  • 17.22. Raphas Co., Ltd.
  • 17.23. Shiseido Company, Limited
  • 17.24. Skyn Iceland
  • 17.25. Vaxess Technologies, Inc.
  • 17.26. Zhuhai Youwe Biotechnology
  • 17.27. Zosano Pharma Corp.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYMER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY CHITOSAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY CHITOSAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY CHITOSAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY HYALURONIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY HYALURONIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY HYALURONIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYLACTIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYLACTIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYLACTIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYVINYLPYRROLIDONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYVINYLPYRROLIDONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYVINYLPYRROLIDONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY COSMETIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY COSMETIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY COSMETIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY PHARMACEUTICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY PHARMACEUTICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY ANALGESIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY ANALGESIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY ANALGESIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY INSULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY INSULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY INSULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. GCC DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GCC DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. GCC DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. GCC DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 115. GCC DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. GCC DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. G7 DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. G7 DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. G7 DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. G7 DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 133. G7 DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. G7 DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. NATO DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. NATO DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. NATO DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. NATO DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 139. NATO DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. NATO DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. CHINA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA DISSOLVABLE MICRONEEDLE PATCHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)